Nov 28 (Reuters) - AstraZeneca PLC:
* SIGNS EXCLUSIVE GLOBAL LICENCE WORTH UP TO $402 MILLION WITH ASTRAZENECA FOR DEVELOPMENT & COMMERCIALISATION OF NRF2 ACTIVATOR PROGRAMME
* C4XD WILL RECEIVE PRE-CLINICAL MILESTONE PAYMENTS WORTH UP TO $16 MILLION AHEAD OF FIRST CLINICAL TRIAL
* IN ADDITION, C4XD IS ELIGIBLE TO RECEIVE A FURTHER POTENTIAL $385.8 MILLION Source text for Eikon: Further company coverage: